scholarly journals Treatment of common warts with the immune stimulant Propionium bacterium parvum

2012 ◽  
Vol 87 (4) ◽  
pp. 585-589 ◽  
Author(s):  
Nilton Nasser
Keyword(s):  
Immune System ◽  
Mucous Membrane ◽  
Saline Solution ◽  
Immune Status ◽  
Intradermal Injection ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Immune Modulator ◽  
Common Warts

BACKGROUND: Warts are epithelial proliferations in the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in size and number according to the patient's immune status. The Propionium bacterium parvum is a strong immune stimulant and immune modulator and has important effects in the immune system and it is able to produce antibodies in the skin. OBJECTIVE: To show the efficacy of the Propionium bacterium parvum in saline solution in the treatment of skin warts. METHODS: A randomized double-blind study. Twenty patients with multiple warts were divided into two groups: one received 0,1ml intradermal injection of placebo solution in just one of the warts and the other received 0,1 ml of saline solution of Propionium bacterium parvum, one dose a month, for 3 to 5 months. RESULTS: Among the 20 patients who participated in the study, ten received the placebo and ten received the saline solution with Propionium bacterium parvum. In 9 patients treated with the Propionium bacterium parvum solution the warts disappeared without scars and in 1 patient it decreased in size. In 9 patients who received the placebo no change to the warts was observed and in 1 it decreased in size. CONCLUSIONS: The immune modulator and immune stimulant Propionium bacterium parvum produced antibodies in the skin which destroyed the warts without scars, with statistically significant results (P<0,001), and cured 90 % of the patients. We suggest the use of the immune stimulant in the treatment of warts.

A Double-Blind Comparative Study with Dolo-Neurobion® and its Separate Constituents in the Treatment of Polyneuritis

1974 ◽  
Vol 2 (1) ◽  
pp. 32-35 ◽  
Author(s):  
E Reyes-Armijo
Keyword(s):  
Comparative Study ◽  
The Other ◽  
Blind Study ◽  
Vitamin B ◽  
Double Blind Study ◽  
Double Blind

A double-blind study was carried out with Dolo-Neurobion® and matching tablets containing: the vitamin B combination, and the metamizol component of the preparation. Forty-five patients suffering from polyneuritis were each treated with eight tablets a day for fourteen days. All fifteen patients who received Dolo-Neurobion were free from pain after treatment but this result was not observed in the patients treated with the vitamin combination alone nor with the metamizol component of the preparation. Dolo-Neurobion also proved more successful after the first half of the treatment (one week), the degree of pain being reduced more significantly than with the other two forms of medication.

Diclofenac Sodium in Ureteral Colic: A Double-Blind Comparison Trial with Placebo

1983 ◽  
Vol 11 (5) ◽  
pp. 303-307 ◽  
Author(s):  
A Vignoni ◽  
A Fierro ◽  
G Moreschini ◽  
M Cau ◽  
A Agostino ◽  
...  
Keyword(s):  
Placebo Group ◽  
Saline Solution ◽  
Diclofenac Sodium ◽  
Complete Relief ◽  
Double Blind Study ◽  
Prostaglandin Synthetase ◽  
Double Blind ◽  
Ureteral Colic ◽  
Comparison Trial ◽  
Blind Comparison

A randomized prospective double-blind study of the analgesic effect of 75 mg intramuscular diclofenac sodium (Voltaren®), a potent prostaglandin synthetase inhibitor, versus placebo (saline solution) was carried out in 131 consecutive patients with acute ureteral colic. Diclofenac provided complete relief of pain 25 minutes after the injection in 59% of the cases, while placebo provided relief in 29% (p < 0·01). Forty patients in the placebo group and seventeen patients in the diclofenac group needed an open injection of 75 mg diclofenac intramuscularly after 25 minutes due to persistent pain. Fifty-four of the fifty-seven patients treated with an open injection of diclofenac achieved complete relief of pain after 30 minutes. There were no side-effects of the treatment.

Dihydroergotamine Nasal Spray in the Treatment Of Attacks of Cluster Headache: A Double-Blind Trial Versus Placebo

Cephalalgia ◽  
1986 ◽  
Vol 6 (1) ◽  
pp. 51-54 ◽  
Author(s):  
Poul Gertz Andersson ◽  
Lennard Tang Jespersen
Keyword(s):  
Cluster Headache ◽  
Mucous Membrane ◽  
Nasal Spray ◽  
Adverse Reactions ◽  
The Other ◽  
Double Blind Trial ◽  
Attack Frequency ◽  
Double Blind ◽  
Blind Trial

A double-blind trial of dihydroergotamine (DHE) nasal spray compared with placebo was carried out in patients with cluster headache. Twenty-five patients were included in the trial. In three patients, all receiving DHE, the pain attacks ceased after five attacks. In the other 22 patients, 133 attacks were treated with placebo and 137 attacks with DHE nasal spray (dosage, 1 mg of DHE). The trial showed that the treatment given has no effect on the attack frequency or the duration of the single attack. However, the treatment had a significant effect on the intensity of the single attacks. It can be concluded that the trial should be repeated, using a larger dosage of DHE. This should be ethically justifiable, since none of the patients had any adverse reactions locally in the mucous membrane of the nose or systemically.

scholarly journals F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study

Blood ◽  
1993 ◽  
Vol 81 (1) ◽  
pp. 9-14 ◽  
Author(s):  
RL Nagel ◽  
E Vichinsky ◽  
M Shah ◽  
R Johnson ◽  
E Spadacino ◽  
...  
Keyword(s):  
Steady State ◽  
Side Effects ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Recombinant Human Erythropoietin ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Human Erythropoietin ◽  
Iron Deficient

Abstract Studies on baboons and preliminary observations in three patients with sickle cell anemia (SS) suggested that high doses of pulse administered recombinant human erythropoietin (rHuEPO) stimulate F-reticulocyte production. We now report on the administration of rHuEPO in a double- blind format to ascertain frequency of response and potential precipitation of side effects. Ten patients were enrolled, but one was discontinued due to the indication of a blood transfusion. Of the other nine, five received rHuEPO in escalating doses (from 400 to 1,500 U per kg twice daily [BID] per week), alternating with a placebo, in blinded fashion. The second group, consisting of four patients, followed an identical protocol (except starting dose was 1,000 U/Kg, BID per week) and were iron supplemented during treatment. The criterion of response was a transient doubling (as a minimum) of the steady-state F- reticulocyte level. We found that none of the five patients in the first group responded to rHuEPO, and two of them became iron deficient, as judged by a significant decrease in ferritin. Of the second group, four patients responded with F-reticulocyte increases. In three patients, open label administration of rHuEPO confirmed the effect. We observed seven painful episodes during this study, two during the EPO administration and five during the placebo arm. Three patients were phlebotomized because the hemoglobin level increased 1.5 g/dL more than steady-state levels. Of the six patients followed-up by percent dense cell determinations, one exhibited increased levels during periods of the treatment, whereas the other five showed no change. No anti-rHuEPO antibodies were detected. We conclude that rHuEPO can stimulate F- reticulocyte response in some patients with sickle cell anemia, without apparent negative clinical side effects. The state of iron stores may be critical. Whether higher doses of rHuEPO and/or a different regimen might induce sustained F cells and fetal hemoglobin increases remains to be determined.

Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers

2011 ◽  
Vol 392 (3) ◽  
Author(s):  
Eric Grouzmann ◽  
Paul Bigliardi ◽  
Monique Appenzeller ◽  
André Pannatier ◽  
Thierry Buclin
Keyword(s):  
Substance P ◽  
Skin Inflammation ◽  
Neutral Endopeptidase ◽  
Intradermal Injection ◽  
Sensory Nerves ◽  
Double Blind Study ◽  
Pain Sensation ◽  
Double Blind ◽  
Burning Pain ◽  
Neurokinin 1

Abstract Substance P (SP), an undecapeptide belonging to the tachykinin family, is released during the activation of sensory nerves, and causes vasodilation, edema and pain through activation of tissular Neurokinin 1 receptors. SP proinflammatory effects are terminated by angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP), while the aminopeptidase dipeptidylpeptidase IV (DPPIV) can also play a role. The aim of this randomized, crossover, double-blind study was to assess the cutaneous vasoreactivity (flare and wheal reaction, burning pain sensation) to intradermal injection of ascending doses of SP in six volunteers receiving a single therapeutic dose of the DPPIV inhibitor sitagliptin or a matching placebo. Cutaneous SP challenges produced the expected, dose-dependent flare and wheal response, while eliciting mild to moderate local pain sensation with little dose dependency. However, no differences were shown in the responses observed under sitagliptin compared with placebo, while the study would have been sufficiently powered to detect a clinically relevant increase in sensitivity to SP. The results of this pilot study are in line with proteolytic cleavage of SP by ACE and NEP compensating the blockade of DPPIV to prevent an augmentation of its proinflammatory action.

scholarly journals Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation

2018 ◽  
Vol 139 (2) ◽  
pp. 106-114 ◽  
Author(s):  
Wictor Aronsson-Kurttila ◽  
Arjang Baygan ◽  
Gianluca Moretti ◽  
Mats Remberger ◽  
Bita Khoein ◽  
...  
Keyword(s):  
Stem Cell ◽  
Immune System ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Stromal Cells ◽  
Hemorrhagic Cystitis ◽  
Double Blind Study ◽  
Median Dose ◽  
Double Blind ◽  
Hematopoietic Stem

Background/Aims: Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. Methods: Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 106/kg (range 0.7-2.5). The patients were given 1 dose (1-4). Results: In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (p = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (p = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. Conclusions: Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 106 DSCs/kg suspended in albumin for treatment of early HC.

TREATMENT OF RAYNAUD SYNDROMES WITH PIRACETAM(NOOTROPIL R),NOOTROPIC AND ANIPLATELET AGENT

1987 ◽  
Author(s):  
M Moriau ◽  
E Lavenne-Pardonge ◽  
C H Col-De Beys
Keyword(s):  
Systemic Disease ◽  
The Other ◽  
Optimal Dosage ◽  
Double Blind Study ◽  
Inhibiting Activity ◽  
Synergic Effect ◽  
Double Blind ◽  
The Third ◽  
Daily Aspirin ◽  
Platelet Functions

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetamThe third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.A fourth double blind study is actually performed

scholarly journals F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study

Blood ◽  
1993 ◽  
Vol 81 (1) ◽  
pp. 9-14 ◽  
Author(s):  
RL Nagel ◽  
E Vichinsky ◽  
M Shah ◽  
R Johnson ◽  
E Spadacino ◽  
...  
Keyword(s):  
Steady State ◽  
Side Effects ◽  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Recombinant Human Erythropoietin ◽  
The Other ◽  
Double Blind Study ◽  
Double Blind ◽  
Human Erythropoietin ◽  
Iron Deficient

Studies on baboons and preliminary observations in three patients with sickle cell anemia (SS) suggested that high doses of pulse administered recombinant human erythropoietin (rHuEPO) stimulate F-reticulocyte production. We now report on the administration of rHuEPO in a double- blind format to ascertain frequency of response and potential precipitation of side effects. Ten patients were enrolled, but one was discontinued due to the indication of a blood transfusion. Of the other nine, five received rHuEPO in escalating doses (from 400 to 1,500 U per kg twice daily [BID] per week), alternating with a placebo, in blinded fashion. The second group, consisting of four patients, followed an identical protocol (except starting dose was 1,000 U/Kg, BID per week) and were iron supplemented during treatment. The criterion of response was a transient doubling (as a minimum) of the steady-state F- reticulocyte level. We found that none of the five patients in the first group responded to rHuEPO, and two of them became iron deficient, as judged by a significant decrease in ferritin. Of the second group, four patients responded with F-reticulocyte increases. In three patients, open label administration of rHuEPO confirmed the effect. We observed seven painful episodes during this study, two during the EPO administration and five during the placebo arm. Three patients were phlebotomized because the hemoglobin level increased 1.5 g/dL more than steady-state levels. Of the six patients followed-up by percent dense cell determinations, one exhibited increased levels during periods of the treatment, whereas the other five showed no change. No anti-rHuEPO antibodies were detected. We conclude that rHuEPO can stimulate F- reticulocyte response in some patients with sickle cell anemia, without apparent negative clinical side effects. The state of iron stores may be critical. Whether higher doses of rHuEPO and/or a different regimen might induce sustained F cells and fetal hemoglobin increases remains to be determined.

Lack of Disulfiram-Like Reaction with Metronidazole and Ethanol

2002 ◽  
Vol 36 (6) ◽  
pp. 971-974 ◽  
Author(s):  
Jukka-Pekka Visapää ◽  
Jyrki S Tillonen ◽  
Pertti S Kaihovaara ◽  
Mikko P Salaspuro
Keyword(s):  
Blood Pressure ◽  
Animal Studies ◽  
Case Reports ◽  
Human Case ◽  
The Other ◽  
Double Blind Study ◽  
Healthy Male ◽  
Double Blind ◽  
Blood Samples ◽  
Human Volunteers

BACKGROUND: Metronidazole, an effective antianaerobic agent, has been reported to have aversive properties when ingested with ethanol. This is thought to be due to the blocking of hepatic aldehyde dehydrogenase (ALDH) enzyme followed by the accumulation of acetaldehyde in the blood. However, based on animal studies and on only 10 human case reports, the existence of metronidazole-related disulfiram-like reaction has recently been questioned. OBJECTIVE: To investigate the possible disulfiram-like properties of metronidazole and ethanol in human volunteers. METHODS: Of 12 healthy male volunteers in this double-blind study, one-half received metronidazole for 5 days and the other half received placebo. All volunteers received ethanol 0.4 g/kg at the beginning of the study. Repeated blood samples were taken every 20 minutes for 4 hours, and blood acetaldehyde and ethanol concentrations were determined. Blood pressure, heart rate, and skin temperature were also measured every 20 minutes for objective signs of a possible disulfiram-like reaction. Volunteers also completed a questionnaire focusing on the subjective signs of disulfiram-like reaction. RESULTS: Metronidazole did not raise blood acetaldehyde or have any objective or subjective adverse effects when used together with ethanol. CONCLUSIONS: This study shows that metronidazole does not have an effect on blood acetaldehyde concentrations when ingested with ethanol and does not have any objective or subjective disulfiram-like properties. However, it is possible that disulfiram-like reaction can occur in some subgroups and by other mechanisms than the inhibition of hepatic ALDH.

Friction blisters and sock fiber composition. A double-blind study

1990 ◽  
Vol 80 (2) ◽  
pp. 63-71 ◽  
Author(s):  
KM Herring ◽  
DH Richie
Keyword(s):  
The Other ◽  
Blind Study ◽  
Cotton Fibers ◽  
Double Blind Study ◽  
Distance Runners ◽  
Long Distance ◽  
Double Blind ◽  
Acrylic Fiber ◽  
Fiber Composition ◽  
Acrylic Fibers

A longitudinal double-blind study was conducted to determine the effect of sock fiber composition on the frequency and size of blistering events in long-distance runners. Thirty-five long-distance runners participated in this study. Two different socks were tested, which were identical in every aspect of construction except fiber composition. One test sock was composed of 100% acrylic fibers, and the other test sock was composed of 100% natural cotton fibers. The results showed that acrylic fiber socks were associated with fewer blistering events and smaller blisters (mm2), when compared directly to cotton fiber socks.

Sign in / Sign up

Export Citation Format

Share Document